News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novo Nordisk A/S (NVO) Files for Regulatory Approval of the Ultra-Long-Acting Insulin Degludec in Japan


12/22/2011 8:18:43 AM

BAGSVAERD, DENMARK--(Marketwire - December 22, 2011) -

Novo Nordisk today announced the submission to the Japanese Pharmaceuticals and Medical Devices Agency, PMDA, of a new drug application for the approval of ultra-long-acting insulin Degludec. This new-generation basal insulin has been developed for the treatment of people with type 1 and type 2 diabetes.

Company Announcemen no 80 / 2011: http://hugin.info/2013/R/1573350/489678.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1573350]


Media:

Katrine Sperling
Tel: (+45) 4442 6718
Email Contact

In North America:
Ken Inchausti
Tel: (+1) 609 514 8316
Email Contact

Investors:

Klaus Bülow Davidsen
Tel: (+45) 4442 3176
Email Contact

Frank Daniel Mersebach
Tel: (+45) 4442 0604
Email Contact

Lars Borup Jacobsen
Tel: (+45) 3075 3479
Email Contact

Jannick Lindegaard
Tel: (+1) 609 786 4575
Email Contact


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES